Inovio Pharmaceuticals(INO)2025-05-13 20:08Financial Performance - INOVIO reported a net loss of 0.51 per share, for Q1 2025, a decrease from a net loss of 1.31 per share, in Q1 2024[10]. - Total operating expenses decreased to 31.5 million in Q1 2024[10]. Research and Development - Research and Development (R&D) expenses decreased to 20.9 million in Q1 2024, primarily due to lower drug manufacturing and immunology expenses[10]. - Interim results from a Phase 1 proof-of-concept trial for DNA-encoded monoclonal antibodies (DMAbs) showed 100% of participants maintained biologically relevant levels of DMAbs at week 72[7]. General and Administrative Expenses - General and Administrative (G&A) expenses decreased to 10.6 million in Q1 2024, attributed to reduced legal expenses and stock-based compensation[10]. Cash Position - Cash, cash equivalents, and short-term investments were 94.1 million as of December 31, 2024[17]. - INOVIO's operational net cash burn is estimated at approximately $22 million for Q2 2025[12]. Future Plans - INOVIO plans to submit a Biologics License Application (BLA) for INO-3107 in mid-2025, with the goal of FDA acceptance by the end of 2025[4]. - INO-3107 has received breakthrough therapy designation from the FDA, and a priority review request is planned[4]. Share Information - As of March 31, 2025, INOVIO had 36.7 million common shares outstanding and 51.3 million on a fully diluted basis[17].